决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
100.0分
★★★★★
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
新诊断多发性骨髓瘤的当前治疗与未来展望
英文原题：Management of Newly Diagnosed Multiple Myeloma Today, and in the Future.
查看英文原题
Management of Newly Diagnosed Multiple Myeloma Today, and in the Future.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去二十年，多发性骨髓瘤患者的治疗选择迅速且广泛地扩展。在过去十年中，基于三药新型药物的诱导方案已被全球公认为适合移植和不适合移植患者的标准实践。将抗CD38单克隆抗体加入四药方案中，已带来更深、更持久的缓解。近年来，四药方案所显示的令人瞩目的结果，在可及之处已改变了临床实践。CAR-T 细胞疗法和双特异性抗体正在初治背景下进行测试，并有可能再次改变新诊断MM的治疗范式。
展开英文摘要原文
Treatment options have expanded rapidly and widely in the past two decades for patients with multiple myeloma. Triplet novel agent-based induction regimens have been accepted as the standard practice wordwide over the last decade both for transplant-eligible and non-eligible patients. The addition of anti-CD38 monoclonal antibodies as part of quadruplet regimens has led to even deeper and longer-lasting responses.
The impressive results shown by the quadruplets havebeen practice-changing where accessible in recent years. Chimeric antigen receptor T cell therapy and bispecific antibodies are being tested in the upfront setting and have the potential to once again shift the paradigm of treatment of newly diagnosed MM.
论文信息
- 作者
- Devasia AJ、Lancman GS、Stewart AK
- 第一作者单位
- Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, 700 University Avenue, Toronto, Ontario, M5G 1X6 Canada.Canada
- 通讯作者单位
- Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, 700 University Avenue, Toronto, Ontario, M5G 1X6 Canada. Electronic address: keith.stewart@uhn.ca.Canada
- 文献类型
- 综述
- 期刊
- Hematology/oncology clinics of North America2024 Apr
- 原文标识
- PubMed 38171937 · DOI 10.1016/j.hoc.2023.12.007